. Author manuscript; available in PMC: 2013 Jun 26.

Published in final edited form as: Cancer Control. 2009 Jan;16(1):14–22. doi: 10.1177/107327480901600103

Table 2. Society of Gynecologic Oncologists: Guidelines for Genetic Risk Assessment for Lynch Syndrome.

Patients with greater than approximately 20%–25% chance of having an inherited predisposition to endometrial, colorectal, and related cancers and for whom genetic risk assessment is RECOMMENDED:	Patients with greater than approximately 5%–10% chance of having an inherited predisposition to endometrial, colorectal and related cancers and for whom genetic risk assessment may be HELPFUL:
Patients with endometrial or colorectal cancer who meet the revised Amsterdam criteria.¹²	Patients with endometrial or colorectal cancer diagnosed < age 50.
At least 3 relatives with a Lynch/HNPCC-associated cancer (colorectal cancer, cancer of the endometrium, small bowel, ureter, or renal pelvis) in one lineage. One affected individual should be a first-degree relative of the other two. At least 2 successive generations should be affected. At least 1 HNPCC-associated cancer should be diagnosed < age 50.
Patients with synchronous or metachronous endometrial and colorectal cancer with the first cancer diagnosed < age 50	Patients with endometrial or ovarian cancer with a synchronous or metachronous colon or other Lynch/HNPCC-associated tumor^* at any age.
Patients with synchronous or metachronous ovarian and colorectal cancer with the first cancer diagnosed < age 50.	Patients with colorectal or endometrial cancer diagnosed at any age with two or more first- or second-degree relatives with Lynch/HNPCC-associated tumors,^* regardless of age.
Patients with colorectal or endometrial cancer with evidence of a mismatch repair defect (ie, MSI or IHC loss of expression of MLH1, MSH2, MSH6 or PMS2).	Patients with a first- or second-degree relative that meets the above criteria.
Patients with a first- or second-degree relative with a known mismatch repair gene mutation.

These tumors include colorectal, endometrial, stomach, ovarian, pancreas, ureter and renal pelvis, biliary tract, and brain (glioblastoma in Turcot syndrome), sebaceous gland adenomas, and keratoacanthomas in Muir-Torre syndrome and carcinoma of the small bowel. HNPCC = hereditary nonpolyposis colorectal cancer. Adapted from Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.